Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia

NCT01885338 is registered in ClinicalTrials.gov with VA Greater Los Angeles Healthcare System as lead sponsor.

NCT NCT01885338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01885338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia
Lead sponsor
VA Greater Los Angeles Healthcare System
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2013
Completion date
May 31, 2014
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia